Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

Chronic illness drug developer Sigilon Therapeutics has filed to go public after raising almost $200m from investors including Eli Lilly.

Pfizer Ventures is the largest individual shareholder in the cancer therapeutics developer, which has filed for a $100m offering.

The University of Cambridge-aligned healthcare and life sciences accelerator has added Novartis as a strategic partner.

The biotech investment firm is the first external life sciences investor to get a fund commitment from pharmaceutical company Sanofi.

Existing backers Takeda, Deerfield and Bay City Capital have provided $10m to help progress research from multiple institutions.

The pharmaceutical firm was one of the contributors to the first fund closed by healthcare tchnology accelerator Start Codon, at $19.7m.

A subsidiary of Sunshine Insurance Group has backed gene diagnostics tool provider Shandong Yingsheng in an eight-digit round set to fund product development.

The child developmental therapy provider closed an $18.1m round co-led by Optum Ventures, which will take a board seat at the company.

Gene editing technology developer Metagenomi advances research from UC Berkeley and has raised a series A co-led by Bayer.